Clinical Trial

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
Protocol Amendment History 1 change
notable Sponsor changed: Celgene -> Bristol-Myers Squibb 2026-04-29
Trial Details
NCT Number NCT06408259
Lead Sponsor Bristol-Myers Squibb
Conditions Multiple Sclerosis, Relapsing-Remitting
Enrollment 194 participants
Start Date 2025-04-08
Primary Completion 2031-04-11 (estimated)
Study Completion 2036-07-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-28